埃克替尼在非小细胞肺癌患者中的疗效观察
详细信息 查看官网全文
- 论文作者：周卉 ; 孟水平
- 年：2016
- 作者机构：安徽省肿瘤医院呼吸肿瘤科;
- 论文关键词：埃克替尼 ; 非小细胞肺癌 ; 疗效观察
- 英文论文关键词：ek for ; Non-small cell lung cancer ; Clinical observation on
- 会议召开时间：2016-11-25
- 会议录名称：湖南中医药大学学报2016/专集：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会论文集
- 语种：中文
- 分类号：R734.2
- 学会代码：HNZY
- 会议名称：国际数字医学会数字中医药分会成立大会暨首届数字中医药学术交流会
- 会议地点：中国广东珠海
- 主办单位：国际数字医学会、Digital Chinese Medicine
- 学会名称：湖南中医药大学期刊杂志社
- 页数：2
- 文件大小：1915k
- 原文格式：D
- 会议级别：全国
摘要
目的:探讨埃克替尼在非小细胞肺癌患者中的疗效。方法:选取2014年1月至2015年12月在医院接受治疗的178例非小细胞肺癌患者作为此次研究对象,比较不同类型非小细胞肺癌应用埃克替尼的治疗效果。结果:178例非小细胞肺癌患者中,EGFR敏感型单突变共44例,占比24.72%,其中exon19为24例,占比13.48%,exon21为20例,占比11.24%;EGFR耐药单突变2例,占比1.12%;双突变3例,占比1.69%;178例患者产生EGFR突变有49例,exon19EGFR敏感型单突变有效率为95.83%,exon21EGFR耐药单突变为95.00%,exon19的治疗效果优于exon21,具有统计学意义(P<0.05);178例患者发生率最高的是皮疹和腹泻,呕吐、皮肤干燥、骨髓抑制和转氨酶异常等并发症较少,其中,Ⅰ级最多,≥Ⅲ级的只有4例,占比2.25%。结论:埃克替尼在EGFR突变非小细胞肺癌患者中疗效显著,其中19外显子突变口服埃克替尼更具优势,临床上值得推广应用。
Objective: to investigate the ek for curative effect in patients with non-small cell lung cancer. Selection Methods: between January 2014 and December 2014 in thehospital for treatment of 178 cases of non-small cell lung cancer patients as the research object, the comparison of different types of non-small cell lung cancer application for ek's therapeuticeffect. Results: 178 cases of non-small cell lung cancer patients, a total of 44 cases of EGFR sensitive single mutations, accounted for 24.72%, including exon19 for 24 cases, accounted for 13.48%, exon21 for 20 cases, accounted for 11.24%; EGFR resistant single mutation in 2 cases, accounted for 1.12%; Double mutation in 3 cases, accounted for 1.69%; 178 cases of patients withEGFR mutations in 49 cases, exon19 EGFR sensitive single mutation effective rate was 95.83%, single exon21 EGFR resistance mutation was 95.00%, the treatment effect of exon19 better thanexon21, statistically significant(P < 0.05); 178 patients is the highest incidence of rash and diarrhea, vomiting, dry skin, bone marrow suppression and transaminase abnormalities such as fewercomplications, among them, the Ⅰ level, most acuity Ⅲ level only 4 cases, accounted for 2.25%. Conclusion: for ek, curative effect in patients with EGFR mutations in non-small cell lungcancer, including 19 exons mutation has more advantages for oral ek, worthy of clinical application.
Objective: to investigate the ek for curative effect in patients with non-small cell lung cancer. Selection Methods: between January 2014 and December 2014 in thehospital for treatment of 178 cases of non-small cell lung cancer patients as the research object, the comparison of different types of non-small cell lung cancer application for ek's therapeuticeffect. Results: 178 cases of non-small cell lung cancer patients, a total of 44 cases of EGFR sensitive single mutations, accounted for 24.72%, including exon19 for 24 cases, accounted for 13.48%, exon21 for 20 cases, accounted for 11.24%; EGFR resistant single mutation in 2 cases, accounted for 1.12%; Double mutation in 3 cases, accounted for 1.69%; 178 cases of patients withEGFR mutations in 49 cases, exon19 EGFR sensitive single mutation effective rate was 95.83%, single exon21 EGFR resistance mutation was 95.00%, the treatment effect of exon19 better thanexon21, statistically significant(P < 0.05); 178 patients is the highest incidence of rash and diarrhea, vomiting, dry skin, bone marrow suppression and transaminase abnormalities such as fewercomplications, among them, the Ⅰ level, most acuity Ⅲ level only 4 cases, accounted for 2.25%. Conclusion: for ek, curative effect in patients with EGFR mutations in non-small cell lungcancer, including 19 exons mutation has more advantages for oral ek, worthy of clinical application.
引文
[1]何小停,刘超英,陆培华,等.埃克替尼治疗晚期非小细胞肺癌的疗效及预后观察[J].中国全科医学,2015,11(9):998-1001.
[2]王文娴,宋正波,张沂平,等.埃克替尼在299例复治晚期非小细胞肺癌患者中的疗效及安全性分析[J].肿瘤,2014,12(7):629-635.
[3]林动,林景辉,何志勇,等.埃克替尼一线治疗EGFR敏感性突变的晚期非小细胞肺癌的疗效观察[J].实用肿瘤杂志,2015,30(3):220-224.
[4]姚舒洋,王若天,李元博,等.埃克替尼对比标准二线化疗治疗晚期非小细胞肺癌的临床观察[J].中国肺癌杂志,2015,27(6):369-373.
[5]朱婷,鲍杨漪,江茜.盐酸埃克替尼治疗老年晚期非小细胞肺癌患者的临床观察[J].实用肿瘤杂志,2014,29(3):259-262.
[6]戴宇翃,王建华,付强,等.盐酸埃克替尼治疗190例晚期非小细胞肺癌疗效及不良反应[J].中国肿瘤,2015,24(2):149-154.
[7]农靖颖,王敬慧,杨新杰,等.盐酸埃克替尼治疗晚期复发非小细胞肺癌的疗效及影响因素分析[J].中国新药杂志,2014,16(13):247-250.
[8]陈剑波,董卫华,何林,等.肺癌的中医病机和药方及盐酸埃克替尼片治疗非小细胞肺癌的临床观察[J].环球中医药,2014,17(s1):27-28.
[2]王文娴,宋正波,张沂平,等.埃克替尼在299例复治晚期非小细胞肺癌患者中的疗效及安全性分析[J].肿瘤,2014,12(7):629-635.
[3]林动,林景辉,何志勇,等.埃克替尼一线治疗EGFR敏感性突变的晚期非小细胞肺癌的疗效观察[J].实用肿瘤杂志,2015,30(3):220-224.
[4]姚舒洋,王若天,李元博,等.埃克替尼对比标准二线化疗治疗晚期非小细胞肺癌的临床观察[J].中国肺癌杂志,2015,27(6):369-373.
[5]朱婷,鲍杨漪,江茜.盐酸埃克替尼治疗老年晚期非小细胞肺癌患者的临床观察[J].实用肿瘤杂志,2014,29(3):259-262.
[6]戴宇翃,王建华,付强,等.盐酸埃克替尼治疗190例晚期非小细胞肺癌疗效及不良反应[J].中国肿瘤,2015,24(2):149-154.
[7]农靖颖,王敬慧,杨新杰,等.盐酸埃克替尼治疗晚期复发非小细胞肺癌的疗效及影响因素分析[J].中国新药杂志,2014,16(13):247-250.
[8]陈剑波,董卫华,何林,等.肺癌的中医病机和药方及盐酸埃克替尼片治疗非小细胞肺癌的临床观察[J].环球中医药,2014,17(s1):27-28.